Somatostatic Agents

Somatostatic agents, more commonly recognized in clinical and pharmacological reference compendia as somatostatin analogs, are a therapeutic class of synthetic peptide compounds designed to mimic the inhibitory actions of endogenous somatostatin

Somatostatic agents, more commonly recognized in clinical and pharmacological reference compendia as somatostatin analogs, are a therapeutic class of synthetic peptide compounds designed to mimic the inhibitory actions of endogenous somatostatin

These agents exert their principal therapeutic effects by binding with high affinity to somatostatin receptors (predominantly SSTR2 and SSTR5), thereby suppressing the hypersecretion of endocrine and paracrine hormones—such as growth hormone, insulin-like growth factor 1, glucagon, and serotonin—while also providing antiproliferative tumor control and reducing splanchnic blood flow Clinically, members of this class (including octreotide, lanreotide, and pasireotide) are primarily utilized in the...

These agents exert their principal therapeutic effects by binding with high affinity to somatostatin receptors (predominantly SSTR2 and SSTR5), thereby suppressing the hypersecretion of endocrine and paracrine hormones—such as growth hormone, insulin-like growth factor 1, glucagon, and serotonin—while also providing antiproliferative tumor control and reducing splanchnic blood flow

These agents exert their principal therapeutic effects by binding with high affinity to somatostatin receptors (predominantly SSTR2 and SSTR5), thereby suppressing the hypersecretion of endocrine and paracrine hormones—such as growth hormone, insulin-like growth factor 1, glucagon, and serotonin—while also providing antiproliferative tumor control and reducing splanchnic blood flow

Clinically, members of this class (including octreotide, lanreotide, and pasireotide) are primarily utilized in the management of acromegaly, symptomatic gastroenteropancreatic neuroendocrine tumors (such as carcinoid syndrome), Cushing disease, and acute bleeding from gastroesophageal varices

Clinically, members of this class (including octreotide, lanreotide, and pasireotide) are primarily utilized in the management of acromegaly, symptomatic gastroenteropancreatic neuroendocrine tumors (such as carcinoid syndrome), Cushing disease, and acute bleeding from gastroesophageal varices